Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.38 |
| ▸ | NRP1 | O14786 | 10/20 | 0.36 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.35 |
| ▸ | NPR1 | P16066 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | LIPC | P11150 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10068133 | 0.87 | LMNA (0.38) | BRD4NRP1 | |
| SCHEMBL10067739 | 0.86 | NRP1 (0.37) | BRD4NRP1SLC10A6NPR1 | |
| SCHEMBL4572265 | 0.86 | NRP1 (0.40) | BRD4NRP1NPR1 | |
| SCHEMBL4572262 | 0.86 | NRP1 (0.53) | NRP1NPR1 | |
| SCHEMBL10068134 | 0.85 | NRP1 (0.37) | NRP1SLC10A6NPR1 | |
| SCHEMBL4572277 | 0.84 | SLC10A6 (0.37) | BRD4NRP1SLC10A6NPR1 | |
| SCHEMBL4572342 | 0.83 | NRP1 (0.49) | NRP1 | |
| SCHEMBL4572339 | 0.80 | EDNRA (0.37) | BRD4NRP1 | |
| SCHEMBL4569889 | 0.79 | BRD4 (0.48) | BRD4SLC10A6ADRA1A | |
| SCHEMBL4572341 | 0.79 | NRP1 (0.43) | NRP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120269864-A1 | Arginine Derivatives with NP-I Antagonistic Activity | GB06/019611.7 THERAPIES LIMITED (GB) | 2012-10-25 | — | — | US | disclosed |
| US-8227606-B2 | Arginine derivatives with NP-1 antagonistic activity | ARK THERAPEUTICS, LTD. (GB) | 2012-07-24 | — | — | US | disclosed |
| US-20120122862-A1 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY | GB06/019611.7 THERAPIES LIMITED (GB) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120269864-A1 | Arginine Derivatives with NP-I Antagonistic Activity | NPFFR1, NPR1, ARG1 | BRD4 2083/4885NRP1 145/4885SLC10A6 1440/4885 |
| US-20120122862-A1 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY | NPFFR1, NPR1, ARG1 | BRD4 2083/4885NRP1 145/4885SLC10A6 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.